A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain.
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Tapentadol (Primary) ; Oxycodone
- Indications Back pain; Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development
- 19 Jul 2010 Results have been published in the journal, Pain Practice, according to a Pricara media release.
- 10 Jun 2009 Results presented at the 10th Annual Congress of the European League Against Rheumatism, 10 Jun 2009.
- 01 Apr 2009 Actual patient number (1122) added as reported by ClinicalTrials.gov
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History